Merck Wins Approval For Diabetes Drug Janumet
This article is from the archive of The New York Sun before the launch of its new website in 2022. The Sun has neither altered nor updated such articles but will seek to correct any errors, mis-categorizations or other problems introduced during transfer.
Merck & Co. won American approval to sell Janumet, the first pill to treat type-2 diabetes by targeting all causes of the disease.
Janumet combines Merck’s Januvia, approved in America last year, with the older drug metformin for treating type-2 diabetes. The new pill was cleared for sale by the Food and Drug Administration and will be available this month, Merck spokeswoman Amy Rose said in an e-mailed statement Saturday.
“It is important mostly as a convenience and from a co-pay perspective,” said Deutsche Bank analyst Barbara Ryan in a March 29 telephone interview.
Januvia, which costs about $5 a pill, is one of the most important new drugs developed by Merck, the third-largest American maker of prescription drugs, and has accounted for about 30 percent of its spending on marketing to doctors since its approval, said Ryan.
